This is a protocol for expanded access use of nogapendekin-alfa inbakicept (N-803/NAI) in participants with lymphopenia induced by chemotherapy, immunotherapy, and/or radiation therapy who may benefit from its use, and who are ineligible to participate in a clinical trial using NAI.

Acceptance Requirements

Adult patients with solid tumors who progressed on standard-of-care treatment requiring second line or greater standard-of-care treatment with:

Chemotherapy and/or

Immune checkpoint inhibitor therapy and/or any therapy investigator deems appropriate at that institution

Radiation therapy